

Resource Summary Report

Generated by [RRID](#) on Aug 28, 2026

SU-DHL-6

RRID:CVCL_2206

Type: Cell Line

Proper Citation

RRID:CVCL_2206

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2206

Proper Citation: RRID:CVCL_2206

Description: Cell line SU-DHL-6 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Diffuse large B-cell lymphoma germinal center B-cell type

Defining Citation: [PMID:83902](#), [PMID:177185](#), [PMID:214220](#), [PMID:371794](#), [PMID:3881165](#), [PMID:7849311](#), [PMID:9738977](#), [PMID:9787181](#), [PMID:10676951](#), [PMID:12169673](#), [PMID:15122589](#), [PMID:16960149](#), [PMID:19278952](#), [PMID:20054396](#), [PMID:20215515](#), [PMID:20628145](#), [PMID:20889926](#), [PMID:22460905](#), [PMID:23699601](#), [PMID:25355872](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25894527](#), [PMID:25960936](#), [PMID:26589293](#), [PMID:26727417](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:30285677](#), [PMID:30629668](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31160637](#), [PMID:31395879](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: TCGA-110-CL cell line panel., Part of: MD Anderson Cell Lines Project., Part of: LL-100 blood cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: SU-DHL-6

Synonyms: SUDHL6, SuDHL6, SU-DHL6, SUDHL-6, SuDHL-6, Sudhl-6, SUD6, Stanford University-Diffuse Histiocytic Lymphoma-6, DHL-6, DHL6

Cross References: CLO:CLO_0037063, EFO:EFO_0002357, AddexBio:C0003011/4672, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-MTAB-7721, ArrayExpress:E-MTAB-7722, ATCC:CRL-2959, BioSample:SAMN03471138, BioSample:SAMN10989551, cancercellines:CVCL_2206, CCRID:5301HUM-KCB1629YJA, CCTCC:GDC0164, Cell_Model_Passport:SIDM00407, ChEMBL-Cells:ChEMBL4295461, Cosmic:687854, Cosmic:850205, Cosmic:1070712, Cosmic:1329089, Cosmic:1517640, Cosmic:1541911, Cosmic:1629935, Cosmic:1636688, Cosmic:1714158, Cosmic:2276340, Cosmic:2297009, Cosmic:2437315, Cosmic-CLP:1331037, DepMap:ACH-000611, DSMZ:ACC-572, DSMZCellDive:ACC-572, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, ENCODE:ENCBS107PVI, ENCODE:ENCBS136LHJ, ENCODE:ENCBS401ZBX, ENCODE:ENCBS782RBW, GDSC:1331037, GEO:GSM1955, GEO:GSM115975, GEO:GSM201348, GEO:GSM380147, GEO:GSM552465, GEO:GSM887655, GEO:GSM888747, GEO:GSM1035311, GEO:GSM1374908, GEO:GSM1670487, IARC_TP53:28323, IGRhCellID:SUDHL6, KCB:KCB 2016029YJ-A, LiGeA:CCLE_578, LINCS_LDP:LCL-1138, Lonza:942, MetaboLights:MTBLS774, PharmacDB:SUDHL6_1504_2019, PRIDE:PXD000589, PRIDE:PXD030304, Progenetix:CVCL_2206, PubChem_Cell_line:CVCL_2206, Wikidata:Q54970721

ID: CVCL_2206

Record Creation Time: 20220427T221612+0000

Record Last Update: 20260815T235918+0000

Ratings and Alerts

No rating or validation information has been found for SU-DHL-6.

No alerts have been found for SU-DHL-6.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 38 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Enssle JC, et al. (2026) Pathogenesis of diffuse large B cell lymphoma proteogenotypes. Cancer cell, 44(7), 1437.

Wu J, et al. (2026) Hi-C for genome-wide detection of enhancer-hijacking rearrangements in routine lymphoid cancer biopsies. Cell genomics, 6(5), 101166.

Isoyama S, et al. (2026) Cooperative Roles of Class IA PI3K Isoforms in Translocation-Related Sarcoma Cell Survival and Proliferation. Cancer research communications, 6(4), 976.

Krishnamoorthy M, et al. (2025) Maplirpacept: a CD47 decoy receptor with minimal red blood cell binding and robust anti-tumor efficacy. *Frontiers in immunology*, 16, 1518787.

Rossi A, et al. (2025) Downregulation of rRNA synthesis by BCL-2 induces chemoresistance in diffuse large B cell lymphoma. *iScience*, 28(5), 112333.

Lüönd F, et al. (2025) DLBCL Cells Emerge after CD19 CAR T Cells with Cross-Antigen Resistance and a Gene Signature Predictive of Clinical CAR T-cell Response. *Blood cancer discovery*, 6(6), 580.

Peled A, et al. (2025) BKT300: A Novel Anti-Leukemic Small Molecule Targeting the Protein Regulator of Cytokinesis 1 (PRC1) Pathway. *Research square*.

Sahasrabuddhe AA, et al. (2025) The FBXO45-GEF-H1 Axis Controls Germinal Center Formation and B-cell Lymphomagenesis. *Cancer discovery*, 15(4), 838.

Mani R, et al. (2025) TP53 upregulation via aurora kinase inhibition overcomes primary failure to venetoclax in BCL2-rearranged lymphomas. *iScience*, 28(6), 112584.

He MY, et al. (2024) GNAS knockout potentiates HDAC3 inhibition through viral mimicry-related interferon responses in lymphoma. *Leukemia*, 38(10), 2210.

Bolomsky A, et al. (2024) IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma. *Cancer cell*, 42(7), 1185.

McCrury M, et al. (2024) Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma. *Molecular cancer therapeutics*, 23(3), 316.

Choi J, et al. (2024) Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas. *Cancer cell*, 42(5), 833.

Eiken AP, et al. (2024) Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects. *Cancer research communications*, 4(5), 1328.

Pieper NM, et al. (2024) Inhibition of bromodomain and extra-terminal proteins targets constitutively active NF κ B and STAT signaling in lymphoma and influences the expression of the antiapoptotic proteins BCL2A1 and c-MYC. *Cell communication and signaling : CCS*, 22(1), 415.

Scuoppo C, et al. (2024) Repurposing NAMPT Inhibitors for Germinal Center B Cell-Like Diffuse Large B-Cell Lymphoma. *Blood cancer discovery*, 5(6), 417.

Rodina A, et al. (2023) Systems-level analyses of protein-protein interaction network dysfunctions via epichaperomics identify cancer-specific mechanisms of stress adaptation. *Nature communications*, 14(1), 3742.

Johnson Z, et al. (2023) IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance. *Cancer research communications*, 3(4), 576.

Donati G, et al. (2022) Targeting mitochondrial respiration and the BCL2 family in high-grade MYC-associated B-cell lymphoma. *Molecular oncology*, 16(5), 1132.

Grubb T, et al. (2022) A Mesenchymal Tumor Cell State Confers Increased Dependency on the BCL-XL Antiapoptotic Protein in Kidney Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 28(21), 4689.